144 related articles for article (PubMed ID: 15932765)
1. The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles.
Herrera C; Klasse PJ; Michael E; Kake S; Barnes K; Kibler CW; Campbell-Gardener L; Si Z; Sodroski J; Moore JP; Beddows S
Virology; 2005 Jul; 338(1):154-72. PubMed ID: 15932765
[TBL] [Abstract][Full Text] [Related]
2. Role of envelope processing and gp41 membrane spanning domain in the formation of human immunodeficiency virus type 1 (HIV-1) fusion-competent envelope glycoprotein complex.
Welman M; Lemay G; Cohen EA
Virus Res; 2007 Mar; 124(1-2):103-12. PubMed ID: 17129629
[TBL] [Abstract][Full Text] [Related]
3. An anti-human immunodeficiency virus multiple antigen peptide encompassing the cleavage region of the env precursor interferes with membrane fusion at a post-CD4 binding step.
Barbouche R; Decroly E; Kieny MP; Fenouillet E
Virology; 2000 Jul; 273(1):169-77. PubMed ID: 10891419
[TBL] [Abstract][Full Text] [Related]
4. Dominant-negative effect of hetero-oligomerization on the function of the human immunodeficiency virus type 1 envelope glycoprotein complex.
Herrera C; Klasse PJ; Kibler CW; Michael E; Moore JP; Beddows S
Virology; 2006 Jul; 351(1):121-32. PubMed ID: 16616288
[TBL] [Abstract][Full Text] [Related]
5. Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity.
Cham F; Zhang PF; Heyndrickx L; Bouma P; Zhong P; Katinger H; Robinson J; van der Groen G; Quinnan GV
Virology; 2006 Mar; 347(1):36-51. PubMed ID: 16378633
[TBL] [Abstract][Full Text] [Related]
6. Characterization of an envelope mutant of HIV-1 that interferes with viral infectivity.
Chen SS; Ferrante AA; Terwilliger EF
Virology; 1996 Dec; 226(2):260-8. PubMed ID: 8955046
[TBL] [Abstract][Full Text] [Related]
7. Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies.
Kang SM; Quan FS; Huang C; Guo L; Ye L; Yang C; Compans RW
Virology; 2005 Jan; 331(1):20-32. PubMed ID: 15582650
[TBL] [Abstract][Full Text] [Related]
8. Ancestral and consensus envelope immunogens for HIV-1 subtype C.
Kothe DL; Li Y; Decker JM; Bibollet-Ruche F; Zammit KP; Salazar MG; Chen Y; Weng Z; Weaver EA; Gao F; Haynes BF; Shaw GM; Korber BT; Hahn BH
Virology; 2006 Sep; 352(2):438-49. PubMed ID: 16780913
[TBL] [Abstract][Full Text] [Related]
9. Mutations at the C-terminus of the simian immunodeficiency virus envelope glycoprotein affect gp120-gp41 stability on virions.
Affranchino JL; González SA
Virology; 2006 Mar; 347(1):217-25. PubMed ID: 16380144
[TBL] [Abstract][Full Text] [Related]
10. Stoichiometry of antibody neutralization of human immunodeficiency virus type 1.
Yang X; Kurteva S; Lee S; Sodroski J
J Virol; 2005 Mar; 79(6):3500-8. PubMed ID: 15731244
[TBL] [Abstract][Full Text] [Related]
11. Truncation of the human immunodeficiency virus-type-2 envelope glycoprotein allows efficient pseudotyping of murine leukemia virus retroviral vector particles.
Höhne M; Thaler S; Dudda JC; Groner B; Schnierle BS
Virology; 1999 Aug; 261(1):70-8. PubMed ID: 10441556
[TBL] [Abstract][Full Text] [Related]
12. Recombinant HIV envelope expressed in an alpha-glucosidase I-deficient CHO cell line and its parental cell line in the presence of 1-deoxynojirimycin is functional.
Fenouillet E; Papandréou MJ; Jones IM
Virology; 1997 Apr; 231(1):89-95. PubMed ID: 9143306
[TBL] [Abstract][Full Text] [Related]
13. Advances in methods for the production, purification, and characterization of HIV-1 Gag-Env pseudovirion vaccines.
Hammonds J; Chen X; Zhang X; Lee F; Spearman P
Vaccine; 2007 Nov; 25(47):8036-48. PubMed ID: 17936444
[TBL] [Abstract][Full Text] [Related]
14. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
[TBL] [Abstract][Full Text] [Related]
15. Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution.
Bontjer I; Land A; Eggink D; Verkade E; Tuin K; Baldwin C; Pollakis G; Paxton WA; Braakman I; Berkhout B; Sanders RW
J Virol; 2009 Jan; 83(1):368-83. PubMed ID: 18922866
[TBL] [Abstract][Full Text] [Related]
16. Effect of epitope position on neutralization by anti-human immunodeficiency virus monoclonal antibody 2F5.
Ou W; Lu N; Yu SS; Silver J
J Virol; 2006 Mar; 80(5):2539-47. PubMed ID: 16474160
[TBL] [Abstract][Full Text] [Related]
17. The HTLV receptor is a widely expressed protein.
Trejo SR; Ratner L
Virology; 2000 Mar; 268(1):41-8. PubMed ID: 10683325
[TBL] [Abstract][Full Text] [Related]
18. Epitopes corresponding to the envelope genetic subtype are present on the surface of free virions of HIV-1 group M primary isolates and can be detected in neutralization assays with extended incubation phases.
Davis D; Donners H; Willems B; Vermoesen T; Heyndrickx L; Colebunders R; van der Groen G
J Med Virol; 2003 Nov; 71(3):332-42. PubMed ID: 12966537
[TBL] [Abstract][Full Text] [Related]
19. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.
Bower JF; Li Y; Wyatt R; Ross TM
Vaccine; 2006 Jun; 24(26):5442-51. PubMed ID: 16621193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
